arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Twist Bioscience Corporation

TWST Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$135.47
▼ -5.1% Today
as of Oct 22, 16:53 ET
Last 30 days +0.53% Sep 14 → Oct 22
$126.97 $147.92 $168.88 $189.83 $210.78 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$144.00
High
$150.14
Low
$131.85
Volume
$3M
Avg Vol
$2M
Mkt Cap
$12.5B
P/E (TTM)
—
Beta
—
52w High
$219.71
52w Low
$23.30
Div Yield
—
Shares Out
$63M

Recent Press Releases & News last 60 days · 21 items

Oct 22 · 20:33 TIKR
Twist Bioscience Sinks 9%, Illumina Down 5% as AI and Genomics Stocks Slide
Oct 13 · 01:32 Simply Wall St.
Is Twist Bioscience (TWST) Quietly Becoming Core Infrastructure for AI-Driven Biofoundry Platforms?
Oct 8 · 11:28 MT Newswires
Jefferies Initiates Twist Bioscience at Hold With $150 Price Target
▸ Show all 21 press releases & news Free account →

TWST earnings at a glance

The options market is pricing a move of about ±10.1% after the report, a range of roughly $121.79 to $149.15 from today's $135.47. Over its last 2 reports the stock rose the next day 0 times and fell 2, moving ±7.7% on average; after the most recent report on May 4, 2026 it moved -7.0%. That means options currently expect more movement than TWST has typically delivered. TWST beat the consensus EPS estimate in 1 of its last 4 reported quarters. Implied volatility is currently 85%. The share price of $135.47 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$23
$220
57% of range
Avg surprise (last 4)
-8.1%
Avg reaction (last 2)
-7.7%
0% positive
Latest IV / EM
85%
EM ±10.1% · $155 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.47$-1.20$-0.94$-0.67$-0.40 Actual $-1.04Actual $-1.01Actual $-0.75Actual $-0.79Actual $-1.47Actual $-0.53Actual $-0.66Est $-0.56Actual $-0.47Est $-0.54Actual $-0.45Est $-0.40Actual $-0.50Actual $-0.62Est $-0.54Actual $-0.56 MarJunDecMarJunDecMar/2025Jun/2025Sep/2025DecMar/2026Jun
Revenue vs Net Income Revenue Net income
$-44M$-2M$40M$82M$124M Dec 24Mar 25Jun 25Dec 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.56 — — — — financials
Mon May 4, 2026Mar/2026 $-0.62 $-0.54 -14.8% +6.1% -7.0% earnings
Wed Dec 31, 2025Dec 2025 $-0.50 — — — — financials
Fri Nov 14, 2025Sep/2025 $-0.45 $-0.40 -12.5% — — earnings
Mon Aug 4, 2025Jun/2025 $-0.47 $-0.54 +13.0% — — earnings
Mon May 5, 2025Mar/2025 $-0.66 $-0.56 -17.9% — -8.4% earnings
Tue Dec 31, 2024Dec 2024 $-0.53 — — — — financials
Sun Jun 30, 2024Jun 2024 $-1.47 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.79 — — — — financials
Sun Dec 31, 2023Dec 2023 $-0.75 — — — — financials
Fri Jun 30, 2023Jun 2023 $-1.01 — — — — financials
Fri Mar 31, 2023Mar 2023 $-1.04 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$118M$111M$104M—$96M$93M$89M—
Cost of revenue$56M$54M$50M—$45M$47M$46M—
Gross profit————————
Operating income$-36M$-46M$-33M—$-30M$-42M$-35M—
Net income$-35M$-44M$-31M—$20M$-39M$-32M—
EPS (diluted)$-0.56$-0.71$-0.50—$0.33$-0.66$-0.53—

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$117M$123M$149M$183M$201M$210M$221M$226M
Inventory$35M$34M$33M$28M$26M$21M$24M$24M
Total current assets$321M$323M$304M$333M$340M$338M$345M$347M
Total assets$672M$676M$638M$642M$644M$596M$609M$614M
Long-term debt————————
Total liabilities$227M$221M$182M$169M$165M$156M$153M$142M
Total equity$446M$455M$456M$473M$478M$440M$456M$473M

Implied volatility — last 90 days

64%84%103%123%143% Jun 07 — IV 77% · EM ±10.7%Jun 08 — IV 85% · EM ±11.2%Jun 09 — IV 78% · EM ±9.8%Jun 10 — IV 83% · EM ±9.8%Jun 11 — IV 81% · EM ±8.9%Jun 12 — IV 68% · EM ±7.0%Jun 15 — IV 95% · EM ±6.9%Jun 16 — IV 86% · EM ±5.1%Jun 17 — IV 144% · EM ±6.0%Jun 19 — IV 76% · EM ±16.7%Jun 22 — IV 83% · EM ±17.3%Jun 23 — IV 77% · EM ±15.8%Jun 24 — IV 78% · EM ±15.7%Jun 25 — IV 69% · EM ±13.5%Jun 26 — IV 76% · EM ±14.5%Jun 29 — IV 82% · EM ±14.5%Jun 30 — IV 81% · EM ±14.0%Jul 01 — IV 78% · EM ±13.0%Jul 02 — IV 68% · EM ±11.0%Jul 03 — IV 71% · EM ±11.0%Jul 06 — IV 80% · EM ±11.1%Jul 07 — IV 80% · EM ±10.6%Jul 08 — IV 80% · EM ±10.0%Jul 09 — IV 87% · EM ±10.2%Jul 10 — IV 81% · EM ±8.9%Jul 13 — IV 92% · EM ±7.7%Jul 14 — IV 101% · EM ±7.3%Jul 15 — IV 98% · EM ±5.8%Jul 16 — IV 102% · EM ±4.3%Jul 20 — IV 85% · EM ±20.2%Jul 21 — IV 88% · EM ±20.5%Jul 22 — IV 101% · EM ±23.1%Jul 23 — IV 90% · EM ±20.3%Jul 24 — IV 90% · EM ±19.9%Jul 27 — IV 88% · EM ±18.4%Jul 28 — IV 97% · EM ±19.8%Jul 29 — IV 102% · EM ±20.4%Jul 30 — IV 101% · EM ±19.8%Jul 31 — IV 107% · EM ±20.5%Aug 03 — IV 89% · EM ±15.8%Aug 04 — IV 79% · EM ±13.6%Aug 05 — IV 77% · EM ±12.8%Aug 06 — IV 73% · EM ±11.8%Aug 07 — IV 72% · EM ±11.3%Aug 10 — IV 76% · EM ±10.5%Aug 11 — IV 77% · EM ±10.1%Aug 12 — IV 75% · EM ±9.3%Aug 13 — IV 73% · EM ±8.6%Aug 14 — IV 64% · EM ±7.1%Aug 17 — IV 74% · EM ±6.1%Aug 18 — IV 85% · EM ±6.2%Aug 19 — IV 112% · EM ±6.6%Aug 20 — IV 101% · EM ±4.2%Aug 24 — IV 82% · EM ±17.2%Aug 25 — IV 87% · EM ±17.7%Aug 26 — IV 89% · EM ±17.7%Aug 27 — IV 90% · EM ±17.6%Aug 28 — IV 84% · EM ±16.1%Aug 31 — IV 86% · EM ±15.2%Sep 01 — IV 81% · EM ±13.9%Sep 02 — IV 82% · EM ±13.7%Sep 03 — IV 71% · EM ±11.5%Sep 04 — IV 70% · EM ±10.9%Sep 07 — IV 79% · EM ±10.9%Sep 08 — IV 80% · EM ±10.5%Sep 09 — IV 77% · EM ±9.6%Sep 10 — IV 77% · EM ±9.1%Sep 11 — IV 76% · EM ±8.4%Sep 14 — IV 83% · EM ±6.9%Sep 15 — IV 84% · EM ±6.1%Sep 16 — IV 101% · EM ±6.0%Sep 17 — IV 104% · EM ±4.3%Sep 21 — IV 86% · EM ±17.9%Sep 22 — IV 82% · EM ±16.8%Sep 23 — IV 82% · EM ±16.5%Sep 24 — IV 97% · EM ±19.1%Sep 25 — IV 95% · EM ±18.1%Sep 28 — IV 98% · EM ±17.4%Sep 29 — IV 92% · EM ±15.9%Sep 30 — IV 92% · EM ±15.4%Oct 01 — IV 91% · EM ±14.8%Oct 02 — IV 84% · EM ±13.1%Oct 06 — IV 85% · EM ±11.2%Oct 07 — IV 82% · EM ±10.2%Oct 08 — IV 85% · EM ±10.1%

Sector peers

HALO
Halozyme Therapeutics, Inc.
$12.6B $124.54+0.1%
TECH
Bio-Techne Corp
$11.4B $72.62+0.1%
EXEL
Exelixis, Inc.
$14.5B $65.31+1.4%
NBIX
Neurocrine Biosciences, Inc.
$14.6B $143.29+0.9%
IBRX
ImmunityBio, Inc.
$10.3B $8.31-5.2%
APGE
Apogee Therapeutics, Inc.
$10.2B $135.07

TWST earnings FAQ

What is TWST's expected move for earnings?

Options currently price a move of about ±10.1%, or $13.68 per share either way from $135.47.

How does TWST stock usually react to earnings?

Across the last 2 reports the average next-day move was ±7.7%, up 0 times and down 2 times.

What is TWST's implied volatility?

TWST's at-the-money implied volatility is about 85% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in